TD Waterhouse Canada’s Aldeyra Therapeutics ALDX Stock Holding History

TD Waterhouse Canada’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25	Hold	15	–	–	﹤0.01%	2268
2025 Q4	$78	Hold	15	–	–	﹤0.01%	1981
2025 Q3	$79	Hold	15	–	–	﹤0.01%	2005
2025 Q2	$59	Hold	15	–	–	﹤0.01%	1931
2025 Q1	$82	Hold	15	–	–	﹤0.01%	1870
2024 Q4	$75	Buy	+15	New	+$77	﹤0.01%	1896

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TD Waterhouse Canada's ALDX Position: Q1 2026 in Review

TD Waterhouse Canada held its Aldeyra Therapeutics (ALDX) position steady in Q1 2026 at 15 shares worth $25. The position accounts for ﹤0.01% of the portfolio, ranked #2268.

TD Waterhouse Canada first reported a position in ALDX in Q4 2024 and has held it in 6 quarters since. The position peaked at $82 in Q1 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

TD Waterhouse Canada held 15 shares of Aldeyra Therapeutics worth $25 as of Q1 2026.
TD Waterhouse Canada left its Aldeyra Therapeutics share count unchanged in Q1 2026.
Aldeyra Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q1 2026, its #2268 holding.
TD Waterhouse Canada first reported a position in Aldeyra Therapeutics in Q4 2024 and has held it in 6 quarters since.
TD Waterhouse Canada's Aldeyra Therapeutics position peaked at $82 in Q1 2025.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on TD Waterhouse Canada's 13F filing for Q1 2026, filed 12 May 2026.